bedford park pharmacy, 5 bedford park corner, london, W4 1LS
Website
-
cureplus limitedEstimated Valuation
£229.6k
Pomanda estimates the enterprise value of CUREPLUS LIMITED at £229.6k based on a Turnover of £735.3k and 0.31x industry multiple (adjusted for size and gross margin).
cureplus limitedEstimated Valuation
£228.8k
Pomanda estimates the enterprise value of CUREPLUS LIMITED at £228.8k based on an EBITDA of £66.4k and a 3.45x industry multiple (adjusted for size and gross margin).
cureplus limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of CUREPLUS LIMITED at £0 based on Net Assets of £-34.7k and 1.98x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cureplus LimitedOverview
Cureplus Limited is a live company located in london, W4 1LS with a Companies House number of 10767920. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in May 2017, it's largest shareholder is
nasrin alsabagh
with a 100% stake. Cureplus Limited is a young,
small sized company, Pomanda has estimated its turnover at
£735.3k with
healthy
growth in recent years.
Pomanda's financial health check has awarded Cureplus Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
3 Strong
2 Regular
5 Weak
Size
annual sales of £735.3k, make it smaller than the average company (£12.6m)
£735.3k - Cureplus Limited
£12.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 15%, show it is growing at a faster rate (7.3%)
15% - Cureplus Limited
7.3% - Industry AVG
Production
with a gross margin of 26.2%, this company has a comparable cost of product (30.9%)
26.2% - Cureplus Limited
30.9% - Industry AVG
Profitability
an operating margin of 9% make it more profitable than the average company (2.5%)
9% - Cureplus Limited
2.5% - Industry AVG
Employees
with 3 employees, this is below the industry average (62)
3 - Cureplus Limited
62 - Industry AVG
Pay Structure
on an average salary of £26.5k, the company has an equivalent pay structure (£26.5k)
£26.5k - Cureplus Limited
£26.5k - Industry AVG
Efficiency
resulting in sales per employee of £245.1k, this is more efficient (£149.9k)
£245.1k - Cureplus Limited
£149.9k - Industry AVG
Debtor Days
it gets paid by customers after 78 days, this is later than average (29 days)
78 days - Cureplus Limited
29 days - Industry AVG
Creditor Days
its suppliers are paid after 44 days, this is quicker than average (63 days)
44 days - Cureplus Limited
63 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Cureplus Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Cureplus Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 114.7%, this is a higher level of debt than the average (59.1%)
114.7% - Cureplus Limited
59.1% - Industry AVG
CUREPLUS LIMITED financials
EXPORT
Cureplus Limited's latest turnover from March 2024 is estimated at £735.3 thousand and the company has net assets of -£34.7 thousand. According to their latest financial statements, Cureplus Limited has 3 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Turnover
735,348
907,226
547,228
486,337
194,724
179,079
172,444
Other Income Or Grants
Cost Of Sales
542,501
658,875
395,813
362,170
146,109
132,560
124,998
Gross Profit
192,847
248,351
151,415
124,167
48,616
46,519
47,447
Admin Expenses
126,456
210,574
159,655
134,186
77,050
113,531
49,189
Operating Profit
66,391
37,777
-8,240
-10,019
-28,434
-67,012
-1,742
Interest Payable
Interest Receivable
168
33
21
128
33
Pre-Tax Profit
66,391
37,777
-8,072
-9,986
-28,413
-66,884
-1,709
Tax
-16,598
-7,178
Profit After Tax
49,793
30,599
-8,072
-9,986
-28,413
-66,884
-1,709
Dividends Paid
Retained Profit
49,793
30,599
-8,072
-9,986
-28,413
-66,884
-1,709
Employee Costs
79,632
122,405
68,528
62,631
61,509
61,593
58,419
Number Of Employees
3
5
3
3
3
3
3
EBITDA*
66,391
37,777
-8,240
27,092
16,205
-12,336
28,554
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Tangible Assets
77,860
105,090
132,320
71,485
94,396
124,835
165,311
Intangible Assets
92,300
106,500
120,700
134,900
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
77,860
105,090
132,320
163,785
200,896
245,535
300,211
Stock & work in progress
56,908
56,893
54,316
50,984
Trade Debtors
158,119
138,960
147,032
44,556
20,359
13,496
15,964
Group Debtors
Misc Debtors
21,938
22,984
30,298
Cash
44,694
21,546
20,695
13,329
misc current assets
total current assets
158,119
138,960
147,032
146,158
120,736
111,491
110,575
total assets
235,979
244,050
279,352
309,943
321,632
357,026
410,786
Bank overdraft
Bank loan
Trade Creditors
66,125
91,775
15,787
416,835
23,053
21,881
20,280
Group/Directors Accounts
393,495
398,795
387,949
other short term finances
hp & lease commitments
other current liabilities
1,990
4,843
4,166
total current liabilities
66,125
91,775
15,787
416,835
418,538
425,519
412,395
loans
hp & lease commitments
Accruals and Deferred Income
6,057
other liabilities
204,526
236,740
372,572
provisions
total long term liabilities
204,526
236,740
378,629
total liabilities
270,651
328,515
394,416
416,835
418,538
425,519
412,395
net assets
-34,672
-84,465
-115,064
-106,892
-96,906
-68,493
-1,609
total shareholders funds
-34,672
-84,465
-115,064
-106,892
-96,906
-68,493
-1,609
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Operating Activities
Operating Profit
66,391
37,777
-8,240
-10,019
-28,434
-67,012
-1,742
Depreciation
22,911
30,439
40,476
23,196
Amortisation
14,200
14,200
14,200
7,100
Tax
-16,598
-7,178
Stock
-56,908
15
2,577
3,332
50,984
Debtors
19,159
-8,072
102,476
2,259
5,817
-9,782
46,262
Creditors
-25,650
75,988
-401,048
393,782
1,172
1,601
20,280
Accruals and Deferred Income
-6,057
6,057
-1,990
-2,853
677
4,166
Deferred Taxes & Provisions
Cash flow from operations
4,984
108,602
-448,799
416,610
6,130
-3,608
-44,246
Investing Activities
capital expenditure
27,230
27,230
31,465
-330,507
Change in Investments
cash flow from investments
27,230
27,230
31,465
-330,507
Financing Activities
Bank loans
Group/Directors Accounts
-393,495
-5,300
10,846
387,949
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-32,214
-135,832
372,572
share issue
-100
100
interest
168
33
21
128
33
cash flow from financing
-32,214
-135,832
372,640
-393,462
-5,279
10,974
388,082
cash and cash equivalents
cash
-44,694
23,148
851
7,366
13,329
overdraft
change in cash
-44,694
23,148
851
7,366
13,329
cureplus limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for cureplus limited. Get real-time insights into cureplus limited's credit score, group structure and payment trends.
Perform a competitor analysis for cureplus limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in W 4 area or any other competitors across 12 key performance metrics.
cureplus limited Ownership
CUREPLUS LIMITED group structure
Cureplus Limited has no subsidiary companies.
Ultimate parent company
CUREPLUS LIMITED
10767920
CUREPLUS LIMITED Shareholders
The sole shareholder of Cureplus Limited is Nasrin Alsabagh.
nasrin alsabagh
100%
cureplus limited directors
Cureplus Limited currently has 2 directors.
The longest serving directors include
Ms Nasrin Alsabagh (Feb 2024) and
Ms Fatima Husham (Feb 2025).
bedford park pharmacy, 5 bedford park corner, london, W4 1LS
Bank
-
Legal Advisor
-
cureplus limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to cureplus limited.
cureplus limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for CUREPLUS LIMITED. This can take several minutes, an email will notify you when this has completed.
cureplus limitedCompanies House Filings - See Documents
